Results 31 to 40 of about 13,380 (189)

Cumulative survival (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).

, 2021
Cumulative survival (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).
Hong Si Nga (4592092), Valter Duro Garcia (5221406), Lilian Monteiro Pereira Palma (4592095), Luis Gustavo Modelli de Andrade (4592089), Roger Kist (7528070), Pedro Augusto Macedo de Souza (11663289), Ida Maria Maximina Fernandes-Charpiot (7586720), Miguel Ernandes Neto (11663283), Silvana Maria Carvalho Miranda (11663286), Gerson Marques Pereira Jr (11663292)   +9 more
core   +1 more source

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement

JCI Insight, 2023
Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding of complement modulation in the human system is required to improve treatment responses and identify off-target ...
Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, Niklas Huntemann, Marc Pawlitzki, Alice Willison, Saskia Räuber, Nico Melzer, Ute Distler, Stefan Tenzer, Kai Stühler, Andreas Roos, Andreas Meisel, Sven G. Meuth, Tobias Ruck   +14 more
doaj   +1 more source

Cumulative incidence of TMA graft loss (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).

, 2021
Cumulative incidence of TMA graft loss (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).
Hong Si Nga (4592092), Valter Duro Garcia (5221406), Lilian Monteiro Pereira Palma (4592095), Luis Gustavo Modelli de Andrade (4592089), Roger Kist (7528070), Pedro Augusto Macedo de Souza (11663289), Ida Maria Maximina Fernandes-Charpiot (7586720), Miguel Ernandes Neto (11663283), Silvana Maria Carvalho Miranda (11663286), Gerson Marques Pereira Jr (11663292)   +9 more
core   +1 more source

Eculizumab improves fatigue in refractory generalized myasthenia gravis [PDF]

, 2019
Purpose: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue ...
Andersen, Henning, O'Brien, Fanny, De Bleecker, Jan, Mantegazza, Renato, Howard, James F, Jr, REGAIN Study Group, the, Patra, Kaushik, Wang, Jing Jing   +7 more
core   +3 more sources

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study

BMC Nephrology, 2019
Background There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of patients with aHUS treated with ...
Jan Menne, Yahsou Delmas, Fadi Fakhouri, Christoph Licht, Åsa Lommelé, Enrico E. Minetti, François Provôt, Eric Rondeau, Neil S. Sheerin, Jimmy Wang, Laurent E. Weekers, Larry A. Greenbaum   +11 more
doaj   +1 more source

Prophylactic or Early Use of Eculizumab and Graft Survival in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome in the United States: Research Letter

Canadian Journal of Kidney Health and Disease, 2021
Introduction: Among kidney transplant recipients (KTRs) with end-stage kidney disease (ESKD) due to atypical hemolytic uremic syndrome (aHUS), recurrence is associated with poor allograft outcomes. We compared graft and patient survival of aHUS KTRs with
Richard A. Plasse, Stephen W. Olson, Christina M. Yuan, Lawrence Y. Agodoa, Kevin C. Abbott, Robert Nee   +5 more
doaj   +1 more source

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

Haematologica, 2010
Background Paroxysmal nocturnal hemoglobinuria is an acquired hemolytic anemia characterized by intravascular hemolysis which has been demonstrated to be effectively controlled with eculizumab.
Anita Hill, Russell P. Rother, Louise Arnold, Richard Kelly, Matthew J. Cullen, Stephen J. Richards, Peter Hillmen   +6 more
doaj   +1 more source

'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. [PDF]

, 2023
BackgroundThe efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG),
REGAIN study group, O'Brien, Fanny, Vissing, John, Jacob, Saiju, Fujita, Kenji P, Howard, James F   +5 more
core   +2 more sources

Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study

BMC Nephrology, 2023
Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may be a therapeutic option. Due to
Thomas Welte, Frederic Arnold, Lukas Westermann, Felix A. Rottmann, Martin J. Hug, Elke Neumann-Haefelin, Athina Ganner   +6 more
doaj   +1 more source

CHAPLE‐Like Enteropathy and Renal Microangiopathy in an Adult Patient With CD46 Deficiency [PDF]

J Clin Lab Anal
We report an adult patient with a homozygous CD46 variant presenting with lifelong protein‐losing enteropathy, intestinal lymphangiectasia, and CVID‐like hypogammaglobulinemia mimicking CHAPLE syndrome. Concurrent renal biopsy revealed PLA2R‐negative membranous nephropathy with chronic thrombotic microangiopathy, establishing multi‐organ complement ...
Erden B, Korkmaz P, Yazici H, Dirim A, Beşışık F, Kahveci N, Kilinc Z, Unal D, Yegit O, Kalaycı T, Hürdoğan Ö, Özlük Y, Büyük M, Gelincik A, Demir S.   +14 more
europepmc   +2 more sources